Electroconvulsive Therapy (ECT): Mechanism, Efficacy, and Future Directions with Dr. Holly Lisanby

In this episode of Psychiatry Boot Camp, Dr. Mark Mullen welcomes Dr. Holly Lisanby for a comprehensive, evidence-based review of electroconvulsive therapy (ECT). Dr. Lisanby traces the mechanism of action from its historical roots in chemically induced convulsive therapy through modern neuroimaging findings, covering the roles of neurotransmitter release, functional connectivity change, anticonvulsant properties, and neuroplasticity, before explaining why the rapidity of ECT's antidepressant response makes neurogenesis an unlikely primary driver. She also introduces the research program she founded developing magnetic seizure therapy (MST), describes the CREST trial demonstrating non-inferior efficacy to right unilateral ECT with significantly less memory loss, and explains why this finding points to the seizure as the primary therapeutic mechanism.
The conversation moves systematically through the full clinical picture and Dr. Mullen and Dr. Lisanby share personal accounts of lives transformed by ECT framing the episode as both a clinical primer and an argument for why no psychiatrist should practice without access to this treatment.
Takeaways:

• ECT has an exceptionally broad therapeutic spectrum and is among the most rapidly acting anti-suicidal interventions in psychiatry.
• Acute ECT courses should be dosed to wellness using measurement-based care with standardized rating scales rather than a fixed number of treatments; stopping too early after initial improvement substantially increases relapse risk.
• Cognitive side effects are meaningfully modifiable: right unilateral electrode placement combined with ultrabrief pulse width produces the least memory impairment without sacrificing efficacy, and switching from unilateral to bilateral should be considered after six treatments without response.
• After an acute ECT course, relapse rates without maintenance treatment approach 75%; the PRIDE trial demonstrated that combination pharmacotherapy (venlafaxine plus lithium) with symptom-titrated algorithm-based maintenance ECT (the STABLE protocol) sustains remission more effectively than medications alone.
• The CREST trial established that magnetic seizure therapy is non-inferior to right unilateral ECT in antidepressant efficacy with significantly less memory loss, providing the strongest evidence to date that the therapeutic mechanism is the seizure itself, not the applied electric field.

References:

1. Right Unilateral Ultrabrief Pulse ECT in Geriatric Depression: Phase 1 of the PRIDE Study
2. Electric field strength and focality in electroconvulsive therapy and magnetic seizure therapy: a finite element simulation study
3. Magnetic seizure therapy of major depression
4. Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy
5. Confirmatory efficacy and safety trial of magnetic seizure therapy versus right unilateral ultra-brief electroconvulsive therapy in depression (CREST-MST): a randomised, double-blind, non-inferiority trial in Canada and the USA
6. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates
7. Relief of expressed suicidal intent by ECT: a consortium for research in ECT study
8. ECT in bipolar and unipolar depression: differences in speed of response
9. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE
10. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study
11. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis
12. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial
13. Antidepressant and cognitive effects of twice- versus three-times-weekly ECT
14. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial
15. A Novel Strategy for Continuation ECT in Geriatric Depression: Phase 2 of the PRIDE Study
16. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy

Chapter: 00:00 ECT Overview
00:19 Meet Dr Lisanby
01:22 ECT Works Fast
03:02 Lives Saved Stories
06:14 Training Access Matters
07:03 How ECT Works
10:16 Magnetic Seizure Therapy
12:46 MST Evidence Trials
14:25 Neuroplasticity BDNF
16:56 What ECT Looks Like
20:11 Who ECT Helps
25:28 How Effective Is ECT
27:54 Maintenance Strategy
37:35 Safety Side Effects
43:45 Stigma And Next Steps

Learn more about your ad choices. Visit megaphone.fm/adchoices